BR112019007039A2 - pirrolidinas substituídas e seus métodos de uso no tratamento de fibrose cística - Google Patents
pirrolidinas substituídas e seus métodos de uso no tratamento de fibrose císticaInfo
- Publication number
- BR112019007039A2 BR112019007039A2 BR112019007039A BR112019007039A BR112019007039A2 BR 112019007039 A2 BR112019007039 A2 BR 112019007039A2 BR 112019007039 A BR112019007039 A BR 112019007039A BR 112019007039 A BR112019007039 A BR 112019007039A BR 112019007039 A2 BR112019007039 A2 BR 112019007039A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- cystic fibrosis
- treatment
- substituted pyrrolidines
- pyrrolidines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a invenção revela compostos de fórmula (i) (i), em que r1, r2, r2a, r3, r3a, r4, r4a e r5 são como definidos aqui. a presen-te invenção se relaciona com compostos e seu uso no tratamento de fibrose cística, métodos para sua produção, composições farmacêuticas que os compreendem e métodos de tratamento de fibrose cística por administração de um composto da in-venção.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662405598P | 2016-10-07 | 2016-10-07 | |
PCT/IB2017/056196 WO2018065962A1 (en) | 2016-10-07 | 2017-10-06 | Substituted pyrrolidines and their use in the treatment of cystic fiibrosis |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019007039A2 true BR112019007039A2 (pt) | 2019-07-16 |
Family
ID=60268420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019007039A BR112019007039A2 (pt) | 2016-10-07 | 2017-10-06 | pirrolidinas substituídas e seus métodos de uso no tratamento de fibrose cística |
Country Status (9)
Country | Link |
---|---|
US (1) | US9981910B2 (pt) |
EP (1) | EP3523293B1 (pt) |
JP (1) | JP2019537564A (pt) |
CN (1) | CN110036009A (pt) |
AU (1) | AU2017339249A1 (pt) |
BR (1) | BR112019007039A2 (pt) |
CA (1) | CA3039659A1 (pt) |
MX (1) | MX2019004018A (pt) |
WO (1) | WO2018065962A1 (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112250627B (zh) | 2014-10-06 | 2024-02-02 | 弗特克斯药品有限公司 | 囊性纤维化跨膜转导调节因子调节剂 |
EP3519401B1 (en) | 2016-09-30 | 2021-09-29 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
IL277491B (en) | 2016-12-09 | 2022-08-01 | Vertex Pharma | Modulatory modulation of transmembrane conductance in cystic fibrosis, pharmaceutical preparations, treatment methods, and a process for creating the modulator |
TW201831471A (zh) | 2017-02-24 | 2018-09-01 | 盧森堡商艾伯維公司 | 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法 |
EP3634402A1 (en) | 2017-06-08 | 2020-04-15 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
CN111051280B (zh) | 2017-08-02 | 2023-12-22 | 弗特克斯药品有限公司 | 制备吡咯烷化合物的方法 |
US10988454B2 (en) | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
US10654829B2 (en) | 2017-10-19 | 2020-05-19 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
MX2020005753A (es) | 2017-12-08 | 2020-08-20 | Vertex Pharma | Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica. |
TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
MD3752510T2 (ro) | 2018-02-15 | 2023-06-30 | Vertex Pharma | Macrociclii ca modulatori ai regulatorului conductanței transmembranare în fibroza chistică, compoziții farmaceutice ale acestora, utilizarea lor în tratamentul fibrozei chistice, și procedeu pentru fabricarea acestora |
EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
US20220089592A1 (en) | 2019-01-18 | 2022-03-24 | Biogen Ma Inc. | Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors |
US11345691B2 (en) | 2019-06-03 | 2022-05-31 | AbbVie Global Enterprises Ltd. | Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
TW202115014A (zh) | 2019-07-12 | 2021-04-16 | 美商奧佛麥德公司 | 用於治療囊腫纖維化之化合物 |
BR112022002605A2 (pt) | 2019-08-14 | 2022-05-03 | Vertex Pharma | Formas cristalinas de moduladores de cftr |
TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
US20220211692A1 (en) | 2021-01-06 | 2022-07-07 | AbbVie Global Enterprises Ltd. | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use |
US20220213041A1 (en) | 2021-01-06 | 2022-07-07 | AbbVie Global Enterprises Ltd. | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use |
WO2024084363A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Use of patatin-like phospholipase domain-containing protein 3 compounds |
WO2024084360A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1765347A4 (en) | 2004-06-04 | 2008-10-01 | Univ California | COMPOUNDS WITH ION TRANSPORTER HEALING EFFECT BY MUTANT CFTR AND ITS USE |
ME02970B (me) | 2004-06-24 | 2018-07-20 | Vertex Pharma | Modulatori atp-vezujućih kasetnih transportera |
US8354427B2 (en) * | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
HUE025553T2 (en) | 2007-05-25 | 2016-02-29 | Vertex Pharma | CFTR modulators |
WO2009003009A1 (en) * | 2007-06-26 | 2008-12-31 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolidine as anti-infectives |
CL2008003651A1 (es) | 2007-12-10 | 2009-06-19 | Novartis Ag | Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias. |
EP2231671B1 (en) | 2007-12-13 | 2013-04-24 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
KR20110074916A (ko) | 2008-10-23 | 2011-07-04 | 버텍스 파마슈티칼스 인코포레이티드 | N-(4-(7-아자비시클로[2.2.1]헵탄-7-일)-2-(트리플루오로메틸)페닐)-4-옥소-5-(트리플루오로메틸)-1,4-디히드로퀴놀린-3-카르복스아미드의 고체 형태 |
EP2382197B1 (en) * | 2008-12-30 | 2016-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US8247436B2 (en) * | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
BR112013007907A2 (pt) | 2010-10-08 | 2016-06-14 | N30 Pharmaceuticals Inc | novos compostos de quinolina substituída como inibidores de s-nitrosoglutationa reductase |
WO2013038386A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038390A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | N-substituted heterocyclyl carboxamides |
ES2716723T3 (es) | 2011-09-20 | 2019-06-14 | Univ North Carolina Chapel Hill | Regulación de los canales de sodio por las proteínas PLUNC |
WO2014180562A1 (en) | 2013-05-07 | 2014-11-13 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis |
SG11201600891UA (en) | 2013-08-08 | 2016-03-30 | Galapagos Nv | Thieno[2,3-c]pyrans as cftr modulators |
AU2015229117A1 (en) | 2014-03-13 | 2016-09-29 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
CA2942386A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
KR102520483B1 (ko) | 2014-10-02 | 2023-04-12 | 다우 글로벌 테크놀로지스 엘엘씨 | 양호한 난연성을 갖는 고주파 용접가능한 에틸렌계 폴리머 조성물 |
SG11201703391VA (en) * | 2014-10-31 | 2017-05-30 | Abbvie S À R L | Substituted chromanes and method of use |
BR112017009194A2 (pt) | 2014-10-31 | 2017-12-26 | Abbvie Sarl | tetra-hidropiranos substituídos e método de uso |
JP2018516932A (ja) | 2015-06-02 | 2018-06-28 | アッヴィ・エス・ア・エール・エル | 置換ピリジンおよび使用方法 |
US9840513B2 (en) | 2015-07-16 | 2017-12-12 | Abbvie S.Á.R.L. | Substituted tricyclics and method of use |
BR112018007145A2 (pt) | 2015-10-09 | 2018-11-06 | AbbVie S.à.r.l. | ácidos pirazolo[3,4-b]piridin-6-carboxílicos substituídos e o seu uso |
PL3359541T3 (pl) | 2015-10-09 | 2021-01-11 | AbbVie Overseas S.à r.l. | N-SULFONYLOWANE PIRAZOLO[3,4-b]PIRYDYNO-6-KARBOKSAMIDY I SPOSÓB ZASTOSOWANIA |
US9873541B2 (en) | 2015-12-24 | 2018-01-23 | Connecticut Container Corp. | Rapid assembling container |
-
2017
- 2017-10-05 US US15/726,075 patent/US9981910B2/en active Active
- 2017-10-06 MX MX2019004018A patent/MX2019004018A/es unknown
- 2017-10-06 EP EP17794779.3A patent/EP3523293B1/en active Active
- 2017-10-06 AU AU2017339249A patent/AU2017339249A1/en not_active Abandoned
- 2017-10-06 CN CN201780075081.3A patent/CN110036009A/zh active Pending
- 2017-10-06 JP JP2019518492A patent/JP2019537564A/ja active Pending
- 2017-10-06 WO PCT/IB2017/056196 patent/WO2018065962A1/en unknown
- 2017-10-06 CA CA3039659A patent/CA3039659A1/en not_active Abandoned
- 2017-10-06 BR BR112019007039A patent/BR112019007039A2/pt not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2019537564A (ja) | 2019-12-26 |
US20180099931A1 (en) | 2018-04-12 |
WO2018065962A1 (en) | 2018-04-12 |
CN110036009A (zh) | 2019-07-19 |
MX2019004018A (es) | 2019-11-12 |
EP3523293B1 (en) | 2021-06-16 |
CA3039659A1 (en) | 2018-04-12 |
AU2017339249A1 (en) | 2019-05-02 |
US9981910B2 (en) | 2018-05-29 |
EP3523293A1 (en) | 2019-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019007039A2 (pt) | pirrolidinas substituídas e seus métodos de uso no tratamento de fibrose cística | |
BR112018074815A2 (pt) | piridinas substituídas com heteroarila e métodos de uso | |
BR112017026132A2 (pt) | piridinas substituídas e métodos de uso | |
ECSP20021913A (es) | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso | |
MX2019004019A (es) | Pirrolidinas sustituidas como moduladores cftr. | |
PH12018502515A1 (en) | New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
BR112019012217A2 (pt) | compostos de amino-triazolopiridina e seu uso no tratamento de câncer | |
BR112019007393A2 (pt) | derivados 6,7,8,9-tetra-hidro-3h-pirazolo[4,3-f]isoquinolina úteis no tratamento de câncer | |
SA518392049B1 (ar) | مشتقات أمونيوم جديدة، عملية لتحضيرها وتركيبات صيدلانية تحتوي عليها | |
BR112018070602A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio | |
BR112017010354B8 (pt) | Compostos de triazolopirimidina, seu uso, e composição farmacêutica | |
CL2020000886A1 (es) | Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih. | |
BR112016016844A2 (pt) | Compostos heterocíclicos | |
BR112017007662A2 (pt) | composto, composição farmacêutica, processo de elaboração de uma composição farmacêutica, método de tratamento de distúrbio ou doença relativa a er, kit de tratamento e uso de composto | |
BR112015027964A2 (pt) | Compostos moduladores do regulador de condutância transmembrana da fibrose cística (cftr), composições farmacêuticas compreendendo os mesmos e uso destes para o tratamento da fibrose cística | |
BR112018008397A2 (pt) | derivados de di-hidroimidazopirazinona úteis no tratamento do câncer | |
BR112017023740A2 (pt) | ?forma sólida de um composto, processo para a preparação de uma forma sólida, composição farmacêutica, método para o tratamento ou prevenção de doenças e utilização de uma forma sólida? | |
BR112018070448A2 (pt) | derivados de aminotiazol úteis como agentes antivirais | |
BR112019024830A2 (pt) | inibidores de bcl6 derivados de benzimidazolona | |
BR112015019412A8 (pt) | inibidores de bace1, seus usos, e composição farmacêutica | |
MX2018009458A (es) | Derivado de sulfonamida heterociclico y medicina que contiene el mismo. | |
BR112018073743A2 (pt) | composto, processo, método para tratamento de infecção bacteriana em um sujeito, uso de um composto, e composições farmacêuticas | |
BR112017015474A2 (pt) | inibidores de bace1 | |
BR112016023991A2 (pt) | ativadores de herg policíclicos | |
BR112022005728A2 (pt) | Compostos de tiazol carboxamida e seu uso para o tratamento de infecções micobacterianas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |